The DST and Outcome in Schizophrenia

Tandon, Rajiv; Mazzara, Cheryl; DeQuardo, John R.

doi:10.1176/ajp.146.12.1648-b

Cited by 6 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The following methodological differences may have contributed to this discrepancy: (1) in their study, the baseline DST was not always performed under drug-free conditions; (2) the association between postdexamethasone cortiso! levels and good l-year outcome noted in their study was somewhat equivocal with regard to the schizophrenic group (Tandon et al 1989b), and (3) because they were studying the association of baseline drug-free DST, their group of initial DST nonsuppressors included both normalizing nonsuppressors (associated with better 4-week outcome in our study) and persistent DS'I nonsuppressors (associated with worse 1-year outcome in our study).…”

Section: Discussionmentioning

confidence: 56%

Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome

Tandon

Mazzara

DeQuardo

et al. 1991

Biological Psychiatry

Self Cite

161

View full text Add to dashboard Cite

To relieve confusion about the clinical correlates and prognostic implications of the dexamethasone suppression test (DST) in schizophrenia, we conducted a DST in 44 schizophrenic inpatients at drug-free baseline and approximately 4 weeks after neuroleptic treatment. Patients were rated on positive, negative, and depressive symptoms at both times. A head computed tomography (CT) scan was performed and measures of ventricle-brain ratio (VBR) obtained. Clinical improvement was monitored at four weeks, and longer-term outcome assessed at 1 year. Seventeen of the 44 patients were DST nonsuppressors at baseline, and five of these remained nonsuppressors at 4 weeks posttreatment. Postdexamethasone plasma cortisol levels were correlated with negative symptoms at baseline (r = 0.45; p less than 0.01), but not after 4 weeks of neuroleptic treatment. Postdexamethasone plasma cortisols were not related to global severity, positive, or depressive symptoms at either timepoint or to VBR. Persistent nonsuppression was associated with poor outcome, but baseline postdexamethasone cortisol levels were unrelated to outcome at 4 weeks and 1 year. The literature on DST in schizophrenia is reviewed and attempts are made to reconcile discrepant findings and to discuss pathophysiological implications.

show abstract

Section: Discussionmentioning

confidence: 56%

Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome

Tandon

Mazzara

DeQuardo

et al. 1991

Biological Psychiatry

Self Cite

161

View full text Add to dashboard Cite

show abstract

Altered proteins of the anterior cingulate cortex white matter proteome in schizophrenia

Clark

Dedova

Cordwell

et al. 2007

Proteomics Clinical Apps

View full text Add to dashboard Cite

Alterations in the circuitry between and within different brain regions including the anterior cingulate cortex (ACC) is implicated in the neuropathology of schizophrenia. The involvement of white matter in schizophrenia is becoming increasingly apparent with reports of structural, morphological and genetic alterations occurring in the disease. The 2-DE was employed to reveal significantly altered proteins within the ACC white matter proteome in a schizophrenia cohort (n = 10) relative to controls (n = 10). From the 423 matched spots between the two groups, the levels of 32 protein spots were altered in the schizophrenia ACC white matter. Of these, 30 spots were identified using MS. The majority of the altered proteins in schizophrenia function in metabolism, the cytoskeleton, and the synapse. These proteomic data suggest that the brain circuitry involving the ACC white matter tracts is altered in schizophrenia, possibly caused by depleted glucose metabolism and altered structural components of this region.

show abstract